Parkman Healthcare Partners LLC Sells 181,752 Shares of Nurix Therapeutics, Inc. $NRIX

Key Points

• Parkman Healthcare Partners LLC reduced its stake in Nurix Therapeutics by 34.2%, selling 181,752 shares and retaining 350,420 shares valued at $4.16 million.
• Nurix Therapeutics reported a quarterly loss of ($0.52) EPS, exceeding analyst expectations, and generated a revenue of $44.06 million compared to anticipated $16.26 million.
• Analysts have mixed ratings for Nurix, with price targets ranging from $26.00 to $30.00, and a consensus rating of "Moderate Buy".

Parkman Healthcare Partners LLC cut its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 34.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 350,420 shares of the company's stock after selling 181,752 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.46% of Nurix Therapeutics worth $4,163,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NRIX. Soleus Capital Management L.P. boosted its stake in Nurix Therapeutics by 97.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after acquiring an additional 1,036,999 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Nurix Therapeutics in the fourth quarter valued at approximately $16,447,000. Vestal Point Capital LP boosted its stake in Nurix Therapeutics by 132.1% in the first quarter. Vestal Point Capital LP now owns 1,125,552 shares of the company's stock valued at $13,372,000 after acquiring an additional 640,552 shares during the last quarter. Millennium Management LLC boosted its stake in Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company's stock valued at $10,388,000 after acquiring an additional 450,262 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Nurix Therapeutics during the fourth quarter worth $4,321,000.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of recent analyst reports. UBS Group reduced their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. HC Wainwright reduced their price target on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, July 14th. Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, July 10th. Oppenheimer restated an "outperform" rating and issued a $30.00 price target (down from $32.00) on shares of Nurix Therapeutics in a report on Thursday, July 31st. Finally, Morgan Stanley set a $16.00 price target on Nurix Therapeutics and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.07.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 5,402 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares of the company's stock, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the firm's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the transaction, the insider directly owned 69,023 shares of the company's stock, valued at approximately $828,966.23. This trade represents a 5.87% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,014 shares of company stock valued at $163,014. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Stock Down 5.2%

Shares of NASDAQ:NRIX traded down $0.50 during midday trading on Tuesday, reaching $9.20. 786,029 shares of the company were exchanged, compared to its average volume of 723,522. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The stock has a fifty day simple moving average of $10.87 and a two-hundred day simple moving average of $11.39. The firm has a market cap of $703.34 million, a PE ratio of -3.52 and a beta of 2.10.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The business had revenue of $44.06 million for the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. As a group, analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.